期刊
JOURNAL OF THORACIC ONCOLOGY
卷 10, 期 7, 页码 1107-1111出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JTO.0000000000000544
关键词
Lung cancer; NSCLC; Fusion gene; VAMP2; NRG1
资金
- Systems biology infrastructure establishment grant by Gwangju Institute of Science & Technology through the ERCSB
- Ministry of Science, ICT, and Future Planning via National Research Foundation of Korea [NRF-2013R1A1A2059405, 2012M3A9B4028766]
- National Research Foundation of Korea [2012M3A9B4028766] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Introduction: Neuregulin 1 (NRG1) has been discovered as the tail moiety of fusion genes with several distinct partner head genes in lung cancers. These fusion genes activate ERBB2/ERBB3 receptor-mediated cell signaling and thereby function as oncogenic drivers. Methods: We have carried out whole-transcriptome sequencing of 100 non-small-cell lung carcinoma tumors and isolated a novel fusion gene consisting of vesicle-associated membrane protein 2 (VAMP2) and NRG1. Reverse transcription-polymerase chain reaction and genomic DNA analysis were used to demonstrate interchromosomal translocation. Immunoblotting and soft agar assays were used to examine stimulating activity of the fusion gene through ERBB2/ERBB3 signaling pathway. Results: The most highly expressed splice variant of VAMP2-NRG1 fusion gene was shown to be membrane bound and display EGF-like domain of NRG1 extracellularly. VAMP2-NRG1 promotes anchorage-independent colony formation of H1568 lung adenocarcinoma cells. Ectopic expression of the fusion gene stimulates phosphorylation of ERBB2 and ERBB3 as well as downstream targets, AKT and ERK, confirming activation of the signaling pathway. Conclusion:VAMP2-NRG1 is a novel oncogenic fusion gene representing a new addition to the list of NRG1 fusion genes, which together may form an important diagnostic and clinical category of lung adenocarcinoma cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据